Rxivist logo

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

By Tesia Bobrowski, Lu Chen, Richard T. Eastman, Zina Itkin, Paul Shinn, Catherine Chen, Hui Guo, Wei Zheng, Sam Michael, Anton Simeonov, Matthew D. Hall, Alexey V. Zakharov, Eugene N. Muratov

Posted 01 Jul 2020
bioRxiv DOI: 10.1101/2020.06.29.178889

COVID-19 is undoubtedly the most impactful viral disease of the current century, afflicting millions worldwide. As yet, there is not an approved vaccine, as well as limited options from existing drugs for treating this disease. We hypothesized that combining drugs with independent mechanisms of action could result in synergy against SARS-CoV-2. Using in silico approaches, we prioritized 73 combinations of 32 drugs with potential activity against SARS-CoV-2 and then tested them in vitro. Overall, we identified 16 synergistic and 8 antagonistic combinations, 4 of which were both synergistic and antagonistic in a dose-dependent manner. Among the 16 synergistic cases, combinations of nitazoxanide with three other compounds (remdesivir, amodiaquine and umifenovir) were the most notable, all exhibiting significant synergy against SARS-CoV-2. The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction. Notably, the combination of remdesivir and hydroxychloroquine demonstrated strong antagonism. Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 2,871 times
  • Download rankings, all-time:
    • Site-wide: 6,172
    • In microbiology: 393
  • Year to date:
    • Site-wide: 28,347
  • Since beginning of last month:
    • Site-wide: 23,815

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide